Abstract
Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4%), 22 (5.6%), five (1.3%), and 14 (3.5%) cases, respectively. HT (14.5%) and venous thrombosis (5.8%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1%) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 891-898 |
| Number of pages | 8 |
| Journal | Anti-cancer drugs |
| Volume | 27 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research
Cite this
Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. / Shirakawa, Tsuyoshi; Nakano, Michitaka; Nio, Kenta; Tamura, Shingo; Komoda, Masato; Kumagai, Hozumi; Uchino, Keita; Odashiro, Keita; Arita, Shuji; Shibata, Yoshihiro; Ariyama, Hiroshi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi.
In: Anti-cancer drugs, Vol. 27, No. 9, 01.09.2016, p. 891-898.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients
AU - Shirakawa, Tsuyoshi
AU - Nakano, Michitaka
AU - Nio, Kenta
AU - Tamura, Shingo
AU - Komoda, Masato
AU - Kumagai, Hozumi
AU - Uchino, Keita
AU - Odashiro, Keita
AU - Arita, Shuji
AU - Shibata, Yoshihiro
AU - Ariyama, Hiroshi
AU - Kusaba, Hitoshi
AU - Akashi, Koichi
AU - Baba, Eishi
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4%), 22 (5.6%), five (1.3%), and 14 (3.5%) cases, respectively. HT (14.5%) and venous thrombosis (5.8%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1%) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.
AB - Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4%), 22 (5.6%), five (1.3%), and 14 (3.5%) cases, respectively. HT (14.5%) and venous thrombosis (5.8%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1%) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84973352146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973352146&partnerID=8YFLogxK
U2 - 10.1097/CAD.0000000000000392
DO - 10.1097/CAD.0000000000000392
M3 - Article
C2 - 27272413
AN - SCOPUS:84973352146
VL - 27
SP - 891
EP - 898
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 9
ER -